BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2011

View Archived Issues

Novel dual specificity protein kinase TTK inhibitors patented

Read More

New phase III data reported on azilsartan medoxomil potassium/chlorthalidone in hypertension

Read More

New insulin-like growth factor I receptor inhibitors synthesized

Read More

New nicotinic acetylcholine alpha7 receptor modulators claimed

Read More

Clovis Oncology expands study to identify patient stratification parameters for CP-4126 trial LEAP

Read More

Phase Ib/II data suggest PCI-32765 is safe in lymphocytic leukemia/small lymphocytic lymphoma

Read More

First-in-human trial assesses azurin-derived P28 peptide in metastatic solid cancers

Read More

First-in-human data disclosed on ONX-0912 in recurrent/refractory solid tumors

Read More

First-in-human study reveals activity of RAF-265 in melanoma

Read More

Blocking Smad1 phosphorylation may reduce diabetic nephropathy

Read More

Japan Tobacco presents novel tyrosine-protein kinase ITK/TSK inhibitors

Read More

EMA continues review of pioglitazone-based medicines

Read More

Sanofi to launch orally disintegrating Allegra tablets in Japan

Read More

Arch Cancer Therapeutics prepares new brain tumor-targeting peptides

Read More

CHMP issues negative opinion on Glybera MAA

Read More

Genmab shelves development activity for zalutumumab

Read More

Evotec and Ono continue ion channel drug discovery collaboration

Read More

Akebia begins new phase IIa AKB-6548 trial in patients with chronic kidney disease and anemia

Read More

CHMP issues negative opinion on Bronchitol for cystic fibrosis

Read More

FDA lifts clinical hold on phase II Cavatak trial in melanoma

Read More

Boehringer Ingelheim begins development program for Ablynx nanobody

Read More

FDA committee recommends approval of Firazyr for hereditary angioedema attacks

Read More

FDA grants orphan drug status to Revimmune in systemic sclerosis and autoimmune hemolytic anemia

Read More

FDA accepts Prochieve progesterone gel NDA for filing

Read More

FDA grants fast track status to SBC-102 in lysosomal acid lipase deficiency

Read More

Arno Therapeutics reports interim phase II data on AR-67 in glioblastoma multiforme

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing